Erythropoietin treatment improves brain function, neuropsychological test scores, and electroencephalography measurements in patients with CKD. Both chronic kidney disease (CKD) and anemia may ...

Roxadustat is now under FDA review for treating anemia of chronic kidney disease, in both non-dialysis-dependent and dialysis-dependent patients, with a PDUFA date of Dec. 20, 2020. So for the last 30 ...

A 65-year-old woman with fourth stage CKD was admitted to a hospital in Wales with a week-long history of shortness of breath and fatigue. A 53-year-old man on home haemodialysis was found to have a ...

A retrospective study found roxadustat to be more effective in improving hemoglobin levels in patients who had with chronic kidney disease (CKD) compared with recombinant human erythropoietin.

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...

In a Swedish real-world study, dialysis and nondialysis patients with high erythropoietin resistance index values had increased risk for major adverse cardiovascular events. Anemia treatment patterns ...

Chronic kidney disease (CKD) is frequently complicated by anaemia, predominantly due to an inadequate production of erythropoietin combined with disruptions in iron metabolism and chronic inflammation ...